Alert icon
We're changing our privacy policy. This stuff matters.  Learn more  Dismiss

Dr. J. Gottesfeld - HDACi for FA - euro-ATAXIA Conference - Dublin, 25th Sept. 2008 - part 1/3

Loading...

Sign in or sign up now!
1,037
Loading...
Alert icon
Sign in or sign up now!
Alert icon

Uploaded by on Apr 18, 2009

Dr Joel Gottesfeld's lab in La Jolla, California (USA), is also working on heterochromatin modifiers as a potential treatment for FRDA, and Dr Gottesfeld started his talk by referencing a paper published by Richard Festenstein's group in 2003 (Nature) as the inspiration. His own work in California has supported the theory that heterochromatin gene silencing occurs in FRDA. The interaction between the active form of the frataxin gene and the inactive (silenced) form is mediated by enzymes called histone deacetylases (HDAC). To see if targeting these enzymes would result in an increase in frataxin, the researchers tested various commercially available HDAC inhibitors and found only one that was slightly active on the frataxin gene (compound BML-210). However they were then able to study derivatives of this compound and identified a compound (4B) which is active at increasing levels of frataxin mRNA and frataxin protein in cells. The next stage was to test the compound in a mouse model of FRDA, and they found that it was able to cross the blood brain barrier and enter the nervous system; it also inhibited HDAC in the brain. There are different classes of HDACs, based on whether they are zinc dependent or non-zinc dependent, and different HDAC inhibitors act on each of the different classes. It is important for research to identify which enzymes are the target, and this gives clues as to the desired chemical properties of the inhibitor. Chemical studies that his team has carried out have now suggested that the class 1 HDAC enzymes are the target for HDAC inhibitors which work on the frataxin gene, and they have identified HDAC3 as the primary target.
The pharmaceutical company Repligen is now working with the active HDAC inhibitors that have been identified, doing pharmacokinetic and toxicology studies to learn more and identify the most effective compounds. A library of derivatives that can be screened for potential treatments has been established, and toxicity studies are going well.
(source: http://health.groups.yahoo.com/group/FA_babelFAmily/message/2399)

Category:

Science & Technology

Tags:

License:

Standard YouTube License

  • likes, 0 dislikes

Link to this comment:

Share to:
see all

All Comments (3)

Sign In or Sign Up now to post a comment!
  • I asked a friend to look at some of the information on friedreich's ataxia a couple of years ago and they told me to ask this question or thought this statement might help.

    They said to me that "a stop codon within either tRNA or MRNA was out of place",

    I'm not sure what that meant but I wanted to ask if this has anything to do with what is going on with friedreich's?

  • My son has friedreich's ataxia. His test for gaa repeats showed 66 gaa repeats.

    How close are they to having a treatment? He is 29 and symptoms are much more pronounced. Please help, Brett's Mom

  • Please, may someone insert subtitula? (to help the not well speaking english people)

Loading...
0 / 00Unsaved Playlist Return to active list
    1. Your queue is empty. Add videos to your queue using this button:
      or sign in to load a different list.
    Loading...Loading...Saving...
    • Clear all videos from this list
    • Learn more